Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications

Nature Biotechnology

Volumn 32, Issue 12, 2014, Pages 1256-1261

  Meade, Bryan R ^a   Gogoi, Khirud ^a   Hamil, Alexander S ^a   Palm Apergi, Caroline ^a   Van Den Berg, Arjen ^a   Hagopian, Jonathan C ^a   Springer, Aaron D ^a   Eguchi, Akiko ^a   Kacsinta, Apollo D ^a   Dowdy, Connor F ^a   Presente, Asaf ^a,b   Lönn, Peter ^a   Kaulich, Manuel ^a   Yoshioka, Naohisa ^a   Gros, Edwige ^a   Cui, Xian Shu ^a   Dowdy, Steven F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; NUCLEIC ACIDS;

DOUBLE-STRANDED RNA; HEPATOCYTE SPECIFIC TARGETING; INNATE IMMUNE RESPONSE; NEGATIVELY CHARGED; PHARMACOKINETIC PROPERTIES; SHORT INTERFERING RNA; SYNTHETIC NANOPARTICLES; SYSTEMIC DELIVERIES;

RNA;

MESSENGER RNA; N ACETYLGALACTOSAMINE; PRODRUG; S ACYL 2 THIOETHYL PHOSPHOTRIESTER; SERUM ALBUMIN; SHORT INTERFERING RIBONUCLEIC NEUTRAL; SMALL INTERFERING RNA; THIOESTER; THIOL ESTER HYDROLASE; UNCLASSIFIED DRUG; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIPOLE; DOSE RESPONSE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VIVO STUDY; INNATE IMMUNITY; LIVER CELL; MESSENGER RNA SYNTHESIS; MOUSE; NONHUMAN; NUCLEOPHILICITY; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SYNTHESIS; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS;

MUS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOPARTICLES; PRODRUGS; RNA, SMALL INTERFERING; SERUM ALBUMIN;

EID: 84920918393     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3078     Document Type: Article

References (35)

1. Castanotto, D. & Rossi, J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426-433 (2009).
2. Pecot, C.V., Calin, G.A., Coleman, R.L., Lopez-Berestein, G. & Sood, A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59-67 (2011).
3. Davidson, B.L. & McCray, P.B. Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329-340 (2011).
4. Behlke, M.A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305-320 (2008).
5. Rettig, G.R. & Behlke, M.A. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20, 483-512 (2012).
6. Bramsen, J.B. & Kjems, J. Chemical modification of small interfering RNA. Methods Mol. Biol. 721, 77-103 (2011).
7. Meade, B.R. & Dowdy, S.F. The road to therapeutic RNA interference (RNAi): tackling the 800 pound siRNA delivery gorilla. Discov. Med. 8, 253-256 (2009).
8. Zhou, J., Shum, K.-T., Burnett, J.C. & Rossi, J.J. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals 6, 85-107 (2013).
9. Kanasty, R., Dorkin, J.R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967-977 (2013).
10. Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
11. Joshua-Tor, L. & Hannon, G.J. Ancestral roles of small RNAs: an Ago-centric perspective. Cold Spring Harb. Perspect. Biol. 3, a003772 (2011).
12. Carthew, R.W. & Sontheimer, E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642-655(2009).
13. Reese, C.B. Oligo- and poly-nucleotides: 50 years of chemical synthesis. Org. Biomol. Chem. 3, 3851-3868 (2005).
14. Gates, K.S. An overview of chemical processes that damage the cellular DNA: spontaneous hydrolysis, alkylation, and reactions with radicals. Chem. Res. Toxicol. 22, 1747-1760 (2009).
15. Grajkowski, A., Wilk, A., Chmielewski, M.K., Phillips, L.R. & Beaucage, S.L. The 2-(N-formyl-N-methyl) aminoethyl group as a potential phosphate/thiophosphate protecting group in solid-phase oligodeoxyribonucleotide synthesis. Org. Lett. 3, 1287-1290 (2001).
16. Dellinger, D.J., Sheehan, D.M., Christensen, N., Lindberg, J.G. & Caruthers, M.H. Solid phase chemical synthesis of phosphonoacetate and thiophosphonoacetate oligodeoxynucleotides. J. Am. Chem. Soc. 125, 940-950 (2003).
17. Tanabe, K., Ando, Y. & Nishimoto, S. Reversible modification of oligodeoxynucleotides: click reaction at phosphate group and alkali treatment. Tetrahedron Lett. 52, 7135-7137 (2011).
18. Krishna, H. & Caruthers, M.H. Alkynyl phosphonate DNA: a versatile "click"able backbone for DNA-based biological applications. J. Am. Chem. Soc. 134, 11618-11631 (2012).
19. Tosquellas, G. et al. The pro-oligonucleotide approach: solid phase synthesis and preliminary evaluation of model pro-dodecathymidylates. Nucleic Acids Res. 26, 2069-2074 (1998).
20. Périgaud, C. et al. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3, 2521-2526 (1993).
21. Lefebvre, I. et al. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38, 3941-3950 (1995).
22. Faraj, A. et al. Intracellular metabolism of beta-L-ddAMP-bis(tbutylSATE), a potent inhibitor of hepatitis B virus replication. Nucleosides Nucleotides 18, 987-988 (1999).
23. Bologna, J.C., Morvan, F. & Imbach, J.L. The prooligonucleotide approach: synthesis of mixed phosphodiester and SATE phosphotriester prooligonucleotides using H-Phosphonate and phosphoramidite chemistries. Eur. J. Org. Chem. 9, 2353-2358 (1999).
24. Guzaev, A.P., Balow, G. & Manoharan, M. Synthesis of chimerical oligonucleotides containing internucleosidic phosphodiester and S-pivaloyl mercaptoethyl phosphotriester linkages. Nucleosides Nucleotides 18, 1391-1392 (1999).
25. Peyrottes, S. et al. SATE pronucleotide approaches: an overview. Mini Rev. Med. Chem. 4, 395-408 (2004).
26. Breslow, R. & Xu, R. Recognition and catalysis in nucleic acid chemistry. Proc. Natl. Acad. Sci. USA 90, 1201-1207 (1993).
27. Beaucage, S.L. Solid-phase synthesis of siRNA oligonucleotides. Curr. Opin. Drug Discov. Devel. 11, 203-216 (2008).
28. Wadia, J.S., Stan, R.V. & Dowdy, S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310-315 (2004).
29. van den Berg, A. & Dowdy, S.F. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 22, 888-893 (2011).
30. Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89-102 (2009).
31. Whitehead, K.A., Dahlman, J.E., Langer, R.S. & Anderson, D.G. Silencing or stimulation? siRNA delivery and the immune system. Annu. Rev. Chem. Biomol. Eng. 2, 77-96 (2011).
32. Judge, A.D. et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505 (2006).
33. Petersen, S. Self-delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference. USPTO 8,691,971 (2014).
34. Sliedregt, L.J.A.M. et al. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J. Med. Chem. 42, 609-618 (1999).
35. Gao, S. et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17, 1225-1233 (2009).